Xeljanz extended induction effective in UC

A majority of patients with ulcerative colitis treated with Xeljanz achieved clinical response after 8 or 16 weeks induction, according to study results.Bruce Sands, MD, from the Icahn School of Medicine, and colleagues wrote that the drug (tofacitinib, Pfizer) has been assessed in several randomized controlled trials, as well as an ongoing open-label extension study.“Here, we assessed short- and long-term efficacy and safety of extended induction with tofacitinib 10 mg twice daily in patients who failed to respond to initial induction treatment,” they wrote.For the study,Read More

Share on facebook
Share on twitter
Share on linkedin